AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04708574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Control
Study NCT04321330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Study NCT01879163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313
Description: Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
Study NCT01879163 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA85A-IMX313
Description: Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
Study NCT01879163 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA85A
Description: Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
Study NCT02074618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise.
Description: Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
Study NCT03787901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morula Vitrification
Description: Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
Study NCT03924518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Hydrochloride
Description: Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
Study NCT03924518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo（Normal saline）
Description: therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
Study NCT02598687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TH-302
Description: TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
Study NCT02598687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HX4 scan
Description: HX 4 scan day 1 and day 8
Study NCT02598687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: 2mg/ml/min
Study NCT02598687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 50 mg/m2
Study NCT02598687 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: 23 x 1.8 Gy
Study NCT02598687 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
Study NCT02458287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab 150mg
Description: Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
Study NCT03787901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morula Vitrification
Description: Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
Study NCT03042585 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: When radiation is given in a way to cover the whole body, it is called total body irradiation.
Study NCT02255955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium and 30mg codeine
Description: Postoperative contramal consumption, pain intensity, side effects
Study NCT02255955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg paracetamol and 30 mg codeine
Description: Postoperative contramal consumption, pain intensity, side effects
Study NCT02255955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: Postoperative contramal consumption, pain intensity, side effects
Study NCT01117181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
Study NCT01117181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
Study NCT01117181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day
Study NCT01117181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychosocial intervention
Description: The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day
Study NCT03016039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation
Description: use of curcumin supplementation as an additive treatment to the conventional treatment
Study NCT03140488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients will be randomized to low dose or high dose oxytocin for induction of labor.
Study NCT03140488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Patients will be randomized to low dose or high dose oxytocin for induction of labor.
Study NCT03718468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC FLU Quadrivalent
Description: A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
Study NCT03718468 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Tetra
Description: A single dose administration of Fluarix Tetra will be through intramuscular injection.
Study NCT03001414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo followed by Autologous EPCs transfected with human eNOS
Description: 4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
Study NCT03001414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs transfected with human eNOS followed by Placebo
Description: 4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
Study NCT03001414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs transfected with human eNOS
Description: 4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
Study NCT00004889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
Study NCT02165644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration.
Study NCT02165644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
Study NCT02165644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
Study NCT00807443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
Study NCT03288623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (85% cocoa)
Description: Dark chocolate (85% cocoa) in tablet
Study NCT03288623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White/Milk chocolate (<35% cocoa)
Description: white or milk chocolate (\<35% cocoa) in tablet
Study NCT02912962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Intervention adapted from the Alert Program ®
Study NCT01678911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gralise
Description: Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication).
Study NCT04649060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Powder for solution for i.v. infusion
Study NCT04649060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets
Study NCT04649060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Solution for s.c. injection
Study NCT04649060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Solution for s.c. injection
Study NCT01823198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01823198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01427686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
Study NCT01427686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
Study NCT02036294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BREATHE program
Description: A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
Study NCT02036294 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard Healthcare Services
Study NCT03498027 — intervention group
Intervention type: DEVICE
Intervention: TaqMan Bacillus anthracis Detection Kit
Description: The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
Study NCT04022993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus Solostar, 100 Units/mL Subcutaneous Solution
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
Study NCT04022993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin RinGlar, 100 Units/mL Subcutaneous Solution
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
Study NCT00961233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled/swallowed budesonide
Description: medication will be nebulized and then swallowed
Study NCT00961233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: viscous/swallowed budesonide
Description: viscous suspension of budesonide will be swallowed
Study NCT04343547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: Tablets, Oral, once daily single dose
Study NCT01823198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01823198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT04343547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202001+DWC202002
Description: Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
Study NCT03933800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula therapy
Study NCT03933800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure therapy
Study NCT04343547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001+DWC202001+DWC202002
Description: Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
Study NCT03338881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-659
Description: \[14C\]-TAK-659 solution.
Study NCT00904644 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
Study NCT03338881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.
Study NCT03537105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
Study NCT00257543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alternative donor bone marrow and cord blood
Description: bone marrow transplant - alternative donors for bone marrow and cord blood transplants
Study NCT00921570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: calcium channel blocker (Amlodipine 10 mg) during 12 weeks
Study NCT01823198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00003587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5.5 day 1 every 21 days X 3
Study NCT00003587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3
Study NCT00003587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
Study NCT00003587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3
Study NCT00003587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
Study NCT00003587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
Study NCT03899233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
Study NCT03899233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid intradermal microinjections
Description: Tranexamic acid 500mg/5ml ampules
Study NCT02458287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab 75mg
Description: Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
Study NCT02458287 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bococizumab 150mg placebo
Description: Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
Study NCT00921570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
Study NCT01285414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubulin
Description: Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide \& Radiation Therapy
Study NCT01285414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide & Radiation Therapy
Description: Temozolomide \& Radiation Therapy
Study NCT03248817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single shot phenylephrine
Description: a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
Study NCT03248817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed infusion phenylephrine
Description: fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
Study NCT03248817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: variable infusion phenylephrine
Description: Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
Study NCT03248817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
Study NCT03248817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
Study NCT03415672 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVaxPro
Description: Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
Study NCT03415672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBAI20
Description: Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
Study NCT01183481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.